Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Five Prime, GSK sign strategic drug discovery alliance
The GSK gains exclusive access to FivePrime’s drug discovery platforms in up to six programs to identify first-in-class agents and new mechanisms relevant to refractory asthma and chronic
The GSK gains exclusive access to FivePrime’s drug discovery platforms in up to six programs to identify first-in-class agents and new mechanisms relevant to refractory asthma and chronic
Biota will establish the US manufacturing of laninamivir, optimize its manufacturing processes, and conduct clinical trials for safety and efficacy in adult and pediatric populations. AMRI will initially
Azul Instant is an all-natural supplement for erectile dysfunction (ED) developed by the company as an alternative to prescription drugs. The addition of these two distributors will allow
The new solution will support the new XEVMPD submission standard, which goes into effect on 2 July 2012. The new XEVMPD regulation mandates that life sciences firms use
BioClinica customers will make use of Paragon’s resources to carry large-scale integration of BioClinica’s eClinical solutions across technology partnerships and client implementations. The Paragon partnership unites BioClinica’s OnPoint
The technology eliminates sample preparation steps in addition to the need for front-end gas or liquid chromatography separation. With the AxION DSA system, sample preparation time is now
VistaGen will utilize the licensed technology to develop hematopoietic precursor stem cells from human pluripotent stem cells, to develop drug screening and cell therapy applications for human blood
The patent makes claims in the uses of a urinary Small MBL-associated protein C-terminal fragment (sMAP) in the diagnosis of ovarian cancer, ovarian cancer monitoring, and patient management.
The addition of the Qualicaps FS3 unit to the company’s manufacturing capabilities is expected to increase overall efficiency at the Phase 2 production scale. The unit, which is
As per the agreement, Merck, through a subsidiary, will gain worldwide rights to develop and commercialize vintafolide. Endocyte will receive a $120m upfront payment and is eligible for